Abstract 9716: Who Needs a Statin? Impact of the New Expert Panel Guidelines for Screening and Management of Dyslipidemia in Children and Adolescents
Introduction: Recent Expert Panel guidelines commissioned by the National Heart, Lung and Blood Institute recommended universal and targeted lipid screening for children and adolescents, together with specification of lipid cutpoints and additional risk factors used in decision-making regarding initiation of lipid-lowering drug therapy. Given the current epidemic of childhood obesity and associated dyslipidemia, we sought to determine the potential impact of these guidelines on the estimated proportion of adolescents would potentially screen positive and be recommended for medication.
Methods: We examined serial cross-sectional assessments using National Health and Nutrition Examination Survey data (1999-2010) of US children ages 12 to 17 years. The weighted proportion of participants meeting guideline screening and management lipid and risk factor cutpoints was determined, and compared to that obtained by applying previous guidelines.
Results: Based only on non-fasting lipid measurement, 24.7% of screened individuals would have dyslipidemia (non-HDL >145 mg/dL + HDL <40 mg/dL) and require further evaluation. Using fasting assessment, 20.3% would screen positive, with 6.6% having high LDL (>130 mg/dL). Of those with fasting assessment, 17.2% were obese, 9.2% smoked, and 2.7% had hypertension. Assuming no improvement with lifestyle therapy and incorporating additional risk factors in decision-making, 0.85% (215,900 US children) might be recommended for statin therapy based on the new guidelines. For severely obese children with BMI > 97th %ile, 3.1% might be recommended for statin therapy. Applying previous guidelines, 0.50% would meet National Cholesterol Education Program 1992 criteria and 1.00% would meet American Academy of Pediatrics 2008 criteria for medication.
Conclusions: Despite the recommendation for universal screening and greater specification regarding risk factors, only a small proportion of adolescents will be recommended for drug therapy with the new guidelines, appropriately targeting those with clustering of risk factors commonly associated with severe obesity, as well as those with familial dyslipidemias.
- © 2012 by American Heart Association, Inc.